Pharma Focus Asia
KP - Choose our fully recyclable blister films

Grünenthal Developed Novel Resiniferatoxin for the Treatment of Knee Osteoarthritis

Grünenthal developed novel resiniferatoxin (RTX), for the pain associated with osteoarthritis (OA) of the knee which is currently undergoing clinical Phase III development.

Resiniferatoxin, is a highly potent Transient Receptor Potential Vanilloid 1 (TRPV1) agonist. By administering it as an intra-articular injection directly into the knee joint, it aims to defunctionalise TRPV1-expressing nociceptors, providing long-lasting pain relief for patients with knee osteoarthritis. Preliminary data showed a significant analgesic effect and functional improvement compared to placebo with a favourable safety profile.

Millions of patients suffering from knee osteoarthritis eagerly await additional treatment options, as the disease currently lacks a cure. Resiniferatoxin holds promise as a potential solution to alleviate the pain associated with this condition.

Resiniferatoxin, if granted approval, holds promising potential as a non-opioid treatment option that can offer enduring pain relief and enhance the functioning of the affected joint. Additionally, it demonstrates a favourable safety profile, further adding to its value as a viable treatment alternative.

U.S. Food and Drug Administration (FDA) grants breakthrough designation for resiniferatoxin for the treatment of pain associated with knee osteoarthritis.

Latest Issue
Get instant
access to our latest e-book
THERMOFISHER SEACertara - Is your drug program on trackMasterControl - Manufacturing demoMasterControl - QMS demoThermo Fisher Scientific - Rapid Mycoplasma TestingThermoFisher Scientific - Save costs on your downstream process todayThermo Fisher Scientific - PeptonesMerck - Mobius® products5th Annual Pharma Manufacturing and Automation Convention 2023DUPHAT 202410TH ANNUAL GCC PHARMACY CONGRESS 202314th Annual Emirates Cardiac Society Conference 2023The International Hand & Wrist Congress 2023LabAsia 2023Pharma & Patient USA 2023Pharma Customer Engagement Europe 2023CHEMICAL INDONESIA 2024INALAB 2024